Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TROXYCA ER vs ADDERALL 30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TROXYCA ER is a fixed-dose combination of oxycodone hydrochloride, a mu-opioid receptor agonist, and naltrexone hydrochloride, a mu-opioid receptor antagonist. Naltrexone is sequestered in the core of the tablet and is not released if taken as directed; however, if crushed or chewed, naltrexone is released and blocks the effects of oxycodone, reducing abuse potential.
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
One capsule orally once daily at approximately the same time each day. The dosage strength should be individualized based on prior opioid use and tolerance. For opioid-naive patients, initiate with the lowest available strength (e.g., 60 mg/3.2 mg). Titrate no more frequently than every 3-7 days as needed.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
Tramadol: 5–6 hours; acetaminophen: 2–3 hours. Clinical context: Steady-state reached in ~1-2 days.
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Oxycodone is extensively metabolized in the liver via CYP3A4 and CYP2D6; naltrexone is metabolized primarily to 6β-naltrexol by dihydrodiol dehydrogenase.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2B6, and CYP3A4.
Renal: ~70% as unchanged drug and metabolites (tramadol, acetaminophen), biliary/fecal: ~30%.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
Tramadol: ~20% bound primarily to albumin; acetaminophen: negligible binding (<5%).
Approximately 20-25% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
Tramadol: ~2.6–3.0 L/kg; acetaminophen: ~0.9–1.0 L/kg. Indicates extensive tissue distribution for tramadol.
Vd: 3-4 L/kg (approximately 210-280 L for a 70 kg adult). This indicates extensive tissue distribution and penetration into the central nervous system.
Oral: ~75% (tramadol); acetaminophen: ~88%.
Oral immediate-release: approximately 75-100%; oral extended-release: approximately 94% relative to immediate-release. Food does not significantly affect absorption but may delay peak concentration.
For GFR 30-89 m L/min: No adjustment recommended. For GFR 15-29 m L/min: Initiate with 60 mg/3.2 mg once daily and titrate cautiously; monitor for respiratory depression. For GFR <15 m L/min: Not recommended due to accumulation of metabolites.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use
For Child-Pugh Class A (mild impairment): No adjustment. For Child-Pugh Class B (moderate impairment): Initiate with 60 mg/3.2 mg once daily and titrate cautiously. For Child-Pugh Class C (severe impairment): Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
Not approved for use in pediatric patients (safety and efficacy not established).
Children 3-5 years: initial 2.5 mg orally once daily; increase by 2.5 mg weekly; usual range 2.5-20 mg/day. Children ≥6 years: initial 5 mg once or twice daily; increase by 5 mg weekly; usual range 5-40 mg/day in divided doses
Initiate with the lowest available strength (60 mg/3.2 mg) once daily and titrate cautiously due to increased sensitivity and risk of respiratory depression; consider renal function decline.
Initiate at 2.5 mg orally once or twice daily; titrate slowly; monitor for cardiovascular effects, insomnia, and weight loss
WARNING: ADDICTION, ABUSE AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion (especially in children),Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Interaction with alcohol,Risk of severe hypotension,Risk of seizures in patients with seizure disorders,Avoid use in patients with gastrointestinal obstruction
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Serotonin syndrome risk when co-administered with serotonergic drugs,Long-term suppression of growth in children,Seizure risk in patients with history of seizures,Peripheral vasculopathy including Raynaud's phenomenon,Visual disturbances due to mydriasis
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment,Known or suspected gastrointestinal obstruction (including paralytic ileus),Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within 14 days of such therapy,Hypersensitivity to oxycodone, naltrexone, or any component of the product
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity to amphetamines,Agitated states,History of drug abuse,During or within 14 days of MAO inhibitor use,Glaucoma
Avoid alcohol and alcoholic beverages. No specific food restrictions; however, a high-fat meal may slightly increase oxycodone absorption, but no dose adjustment needed.
Avoid high-fat meals as they delay absorption; avoid acidic foods (e.g., citrus) and vitamin C supplements within 1 hour of dosing as they decrease absorption; limit caffeine and other stimulants to avoid additive cardiovascular effects.
First trimester: No adequate human data; animal studies show no teratogenicity at exposures up to 10 times MRHD. Second/third trimester: Prolonged use may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Avoid chronic use.
Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, lassitude). Chronic use may lead to neonatal toxicity.
M/P ratio unknown. Oxycodone and naltrexone enter breast milk in low amounts; monitor infant for sedation and respiratory depression. Benefits may outweigh risks with short-term use.
Excreted in breast milk. M/P ratio unknown. Potential for stimulant effects in infant (e.g., irritability, poor feeding, insomnia). Caution advised; consider alternative feeding methods.
No specific dose adjustments recommended; pharmacokinetic changes (e.g., increased clearance, decreased protein binding) may necessitate careful titration. Use lowest effective dose for shortest duration.
No established dosing guidelines. Due to increased plasma volume and clearance, dose may need titration to clinical effect, but avoid supratherapeutic doses. Use lowest effective dose.
TROXYCA ER is a fixed-dose combination of oxycodone and naltrexone designed for abuse deterrence. The naltrexone is sequestered and released only if the tablet is crushed, precipitating withdrawal in opioid-dependent individuals. It is not indicated for PRN use; only for around-the-clock management of severe chronic pain. Avoid in patients with opioid dependence due to risk of precipitated withdrawal. Do not administer with alcohol or other CNS depressants due to additive effects. Monitor for respiratory depression, especially in elderly or debilitated patients.
For ADHD: start low, go slow; monitor weight and height in children; avoid late doses to prevent insomnia; check for abuse/diversion; screen for bipolar disorder and hypertension; consider urine drug screen before prescribing; avoid MAOIs within 14 days; use with caution in seizure disorders and glaucoma.
Take exactly as prescribed; do not crush, chew, or dissolve tablets.,This medication contains an opioid that can be habit-forming; use only for your pain and do not share with others.,Do not drink alcohol while taking this medication; it can increase the risk of severe drowsiness and respiratory depression.,Common side effects include constipation, nausea, dizziness, and drowsiness; report severe or persistent symptoms.,Store safely out of reach of children and dispose of unused tablets via a take-back program or flushing (per FDA guidelines).,Do not stop abruptly without talking to your doctor to avoid withdrawal symptoms.
Take exactly as prescribed; do not crush or chew capsules.,Take the first dose upon waking; avoid afternoon/evening doses.,May cause insomnia, loss of appetite, or nervousness.,Do not drink alcohol while taking this medication.,Report chest pain, palpitations, shortness of breath, or mood changes.,Store securely; do not share medication with others.,Regular blood pressure and heart rate monitoring is necessary.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TROXYCA ER vs ADDERALL 30, answered by our medical review team.
TROXYCA ER is a Opioid Analgesic (with abuse-deterrent properties) that works by TROXYCA ER is a fixed-dose combination of oxycodone hydrochloride, a mu-opioid receptor agonist, and naltrexone hydrochloride, a mu-opioid receptor antagonist. Naltrexone is sequestered in the core of the tablet and is not released if taken as directed; however, if crushed or chewed, naltrexone is released and blocks the effects of oxycodone, reducing abuse potential.. ADDERALL 30 is a CNS Stimulant that works by Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TROXYCA ER and ADDERALL 30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TROXYCA ER is: One capsule orally once daily at approximately the same time each day. The dosage strength should be individualized based on prior opioid use and tolerance. For opioid-naive patients, initiate with the lowest available strength (e.g., 60 mg/3.2 mg). Titrate no more frequently than every 3-7 days as needed.. The standard adult dose of ADDERALL 30 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TROXYCA ER and ADDERALL 30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TROXYCA ER is classified as Category C. First trimester: No adequate human data; animal studies show no teratogenicity at exposures up to 10 times MRHD. Second/third trimester: Prolonged use may cause neonatal opioid wit. ADDERALL 30 is classified as Category C. Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.